The development of biosimilars has focused on the "big six" monoclonal antibodies or biologics. These include rituximab and trastuzumazumab. These are among the most common oncology treatments. A panel of the FDA found that most of these biosimilars were safe and effective, but that no oncology biosimilars were interchangeable with their bio-originators.
A Oncology Biosimilars is a biological product that closely mimics and is identical to a previously approved reference product. These are less expensive than branded or certified items. Several oncology biologics have already lost their patents, and others are about to expire. Oncology Biosimilars are predicted to gain popularity as more products lose their patents.
Read More @ https://expressmyblog.blogspot.com/2022/06/oncology-biosimilars-are-results-of.html
